Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Single-Arm Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of MT-125 Monotherapy With Radiation in Newly Diagnosed Glioblastoma

NCT07185880 is registered in ClinicalTrials.gov with Myosin Therapeutics Inc. as lead sponsor.

NCT NCT07185880
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07185880 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Single-Arm Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of MT-125 Monotherapy With Radiation in Newly Diagnosed Glioblastoma
Lead sponsor
Myosin Therapeutics Inc.
Phase
Phase 1/2
Overall status
Recruiting
Start date
April 1, 2026
Completion date
February 29, 2032
Enrollment
36 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma (gbm)